A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Namodenoson (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Can-Fite BioPharma
- 18 Dec 2017 According to a Can-Fite BioPharma, company anticipates data release in second half of 2018.
- 09 Aug 2017 Status changed from recruiting to active, no longer recruiting according to a can-Fite BioPharma media release.
- 18 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.